Table 1.
Key Input parameters
| Parameter or input | Value | Reference |
|---|---|---|
| Sexual risk characteristics | ||
| Proportion of population who are abstinent | 21.0% | 33 |
| Probability of monogamous relationship (if sexually active) | ||
| Men who have sex with women (MSW) | 78.2% | 34 |
| Men who have sex with men (MSM) | 55.8% | 34 |
| Women who have sex with men (WSM) | 91.1% | 34 |
| Women who have sex with women (WSW) | 48.9% | 34 |
| Probability of multiple partnerships (if sexually active) | ||
| MSW | 21.8% | 34 |
| MSM | 44.2% | 34 |
| WSM | 8.9% | 34 |
| WSW | 51.1% | 34 |
| Proportion of men who are MSM | 5.6% | 34 |
| Proportion of men who are MSW | 94.4% | 34 |
| Proportion of women who are WSW | 2.4% | 34 |
| Proportion of women who are WSM | 97.6% | 34 |
| Injection Drug Use Characteristics | ||
| Proportion of population that injects drugs | 1.43% | 35 |
| Proportion of injection drug users (IDUs) who have unsafe injection practices | 32% | 36 |
| Proportion of IDUs who are male | 70% | 36 |
| Sexual and IDU transmission | ||
| Transmission risk per sex act | ||
| Male-to-male | 0.00167 | 37 |
| Female-to-male | 0.00042 | 37 |
| Male-to-female | 0.00081 | 37 |
| Transmission risk per unsafe needle sharing act | 0.003 | 38 |
| Relative risk of transmission dependent on viral load | 0.16 – 9.03 | 39 |
| Sex acts (per partnership) per year | 89 | 40 |
| Shared injections per year | 70 | Assumption |
| HIV risk behaviors and biological/behavioral modifiers of transmission | ||
| Prevalence of untreated sexually transmitted infection | 6.9% | 41, 42 |
| Prevalence of unhealthy alcohol use | 5% | 43 |
| Prevalence of consistent condom usage | 35% | 34 |
| HIV disease related | ||
| Probability of annual HIV test | 31% | 34 |
| Probability of linkage to care | 75% | Unpublished NYC DOMH data |
| Probability of initiating ART if in care | 87% | Unpublished NYC DOMH data |
| ART compliance | 62% | 44 |
| Demographics | ||
| Age-related mortality rate | 0.0068 (6.8/1000 pop) | 45 |
| Fertility rate | 0.0156 (15.6/1000 pop/year) | 45 |
| Interventions | ||
| VBS hit rate | 0.496% | BCAP Trial |
| RDS-C hit rate | 0.931% | BCAP Trial |
| RDS-A hit rate | 2.81% | BCAP Trial |
| Costs | ||
| VBS per person enrolled | $368 | BCAP Trial |
| RDS-C per person enrolled | $648 | BCAP Trial |
| RDS-A per person enrolled | $531 | BCAP Trial |
| Cost of care for individuals with CD4<100 | $58,320 | 46 |
| Cost of care for individuals with CD4>100 | $30,312 | 46 |
ART: antiretroviral therapy